PT-141 10mg reconstitution and dosage explained: how much bacteriostatic water to add, how many units per dose, and typical 1.75 mg protocols for adults.
To reconstitute a 10 mg vial of PT-141, add 1–2 mL of bacteriostatic water and swirl the vial gently until the powder dissolves completely — never shake it. At 2 mL of water the concentration is 5 mg/mL, so the standard 1.75 mg subcutaneous dose equals 0.35 mL, or 35 units on a U-100 insulin syringe. PT-141 (bremelanotide) is a melanocortin receptor agonist that is approved in the United States only as the brand-name autoinjector Vyleesi, and only for premenopausal women with hypoactive sexual desire disorder (HSDD).
What PT-141 Is and What a 10 mg Vial Actually Contains
PT-141 is a synthetic peptide that activates melanocortin receptors in the brain. Researchers believe it influences sexual desire through pathways that do not depend on blood flow or testosterone.
Vyleesi, the approved product, delivers 1.75 mg of bremelanotide subcutaneously through a single-use autoinjector. The 10 mg vials sold by research-peptide vendors contain the same active molecule, but they are labeled for research use only.
PT-141 sold as a 10 mg research vial is not FDA-approved for human use, and its purity, sterility, and actual peptide content are not verified by the FDA.
How to Reconstitute a 10 mg PT-141 Vial
Reconstitution means dissolving the freeze-dried powder in a liquid so it can be drawn into a syringe. Bacteriostatic water — sterile water containing 0.9% benzyl alcohol — is the usual choice because the preservative slows bacterial growth in a multi-dose vial.
Most guides to pt-141 reconstitution and dosage start with the same two decisions: how much water to add and how much volume to inject. The water volume sets the concentration, and the concentration determines how many units you draw.
- Wash your hands and wipe the tops of both vials with alcohol swabs.
- Draw 1–2 mL of bacteriostatic water into a sterile syringe with a needle.
- Insert the needle into the PT-141 vial at an angle, aiming the stream at the glass wall rather than directly at the powder.
- Swirl the vial slowly between your fingers until the solution is clear. Do not shake.
- Label the vial with the date and the concentration, then refrigerate it.
A cloudy solution, visible particles, or a gel-like texture means the peptide has not dissolved properly or has degraded. Discard it rather than injecting it.
| Bacteriostatic water added | Concentration | 1 mg dose | 1.75 mg dose | 2 mg dose |
|---|---|---|---|---|
| 1 mL | 10 mg/mL | 0.10 mL (10 units) | 0.175 mL (17.5 units) | 0.20 mL (20 units) |
| 2 mL | 5 mg/mL | 0.20 mL (20 units) | 0.35 mL (35 units) | 0.40 mL (40 units) |
| 3 mL | 3.33 mg/mL | 0.30 mL (30 units) | 0.525 mL (52.5 units) | 0.60 mL (60 units) |
PT-141 10 mg Dosage: How Many Units to Draw
The approved bremelanotide dose is 1.75 mg injected under the skin of the abdomen or thigh. That dose is the same whether you are using the brand-name autoinjector or calculating from a reconstituted vial.
Working out pt-141 10mg dosage in units depends entirely on your concentration. With 2 mL of water in a 10 mg vial, a pt 141 10mg dosage of 1.75 mg works out to 35 units on a U-100 insulin syringe, where 100 units equal 1 mL.
The FDA-approved PT-141 dose is 1.75 mg subcutaneously, no more than once in 24 hours and no more than 8 doses in a month.
Higher doses do not reliably produce stronger effects. In early clinical work, much larger doses delivered by nasal spray were abandoned because of sharp rises in blood pressure.
| Use case | Typical dose | Frequency limit | FDA status |
|---|---|---|---|
| Premenopausal women with HSDD | 1.75 mg SC | Once per 24 hours, max 8 per month | Approved (Vyleesi) |
| Men (off-label) | 1.75–2 mg SC | Once per 24 hours, max 8 per month | Not approved |
| Research-only vial use | 1–2 mg SC | Not established | Not approved |
PT-141 10 mg Dosing for Men vs. Women
Women
Bremelanotide is approved for premenopausal women with acquired, generalized HSDD. The pt-141 dosage for women in the label is a flat 1.75 mg — there is no weight-based adjustment and no titration step.
Clinicians typically advise injecting about 45 minutes before anticipated sexual activity.
Men
Bremelanotide is not FDA-approved for men, and clinical trials in men with erectile dysfunction have not shown consistent benefit. Any pt-141 10mg dosage for men is therefore off-label and based on limited data.
Reports from researchers and clinicians usually describe 1.75 mg to 2 mg subcutaneously, the same range used in women, with the same 24-hour and monthly limits.
Timing, Side Effects, and Safety
Bremelanotide peaks in the blood roughly an hour after injection and has a half-life of about 2.7 hours. Injecting 45 minutes before sexual activity matches that profile.
The most common side effects reported in trials were nausea, flushing, headache, and injection-site reactions. Nausea was the most frequent reason women stopped treatment.
- Transient increases in blood pressure and heart rate — avoid PT-141 if you have uncontrolled hypertension or heart disease.
- Focal hyperpigmentation of the skin with more frequent dosing.
- More intense nausea when PT-141 is combined with alcohol.
Anyone considering PT-141 should talk with a healthcare professional first, especially if they take blood pressure medication or have cardiovascular risk factors.
Storage and Stability
Store the unmixed powder in the refrigerator or as the supplier directs, protected from light. Once reconstituted, keep the vial at 2–8 °C and follow the vendor's stability guidance, which is often 30 days when bacteriostatic water is used.
Do not freeze the reconstituted solution, and do not leave it in a warm car or in direct sunlight. A solution that changes color or develops particles should be discarded.
Frequently Asked Questions
How do I reconstitute a 10 mg PT-141 vial?
Add 1–2 mL of bacteriostatic water to the vial and swirl gently until the powder dissolves completely; never shake it. With 2 mL of water the concentration is 5 mg/mL, which makes the standard 1.75 mg dose easy to calculate. Refrigerate the reconstituted vial at 2–8 °C and discard any solution that looks cloudy or contains particles.
What is 1.75 mg of PT-141 in units?
It depends on the concentration you mixed. In a 10 mg vial mixed with 2 mL of bacteriostatic water (5 mg/mL), 1.75 mg equals 0.35 mL, which is 35 units on a U-100 insulin syringe. With only 1 mL of water added, the same 1.75 mg dose is 17.5 units.
Is PT-141 FDA-approved for men?
No. Bremelanotide is FDA-approved only as Vyleesi, a 1.75 mg autoinjector for premenopausal women with hypoactive sexual desire disorder. Use in men is off-label, and trials in men with erectile dysfunction have not shown consistent benefit. Anyone using it off-label should discuss the risks with a healthcare professional.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.